# FDA Inspection 971651 - Daiichi Sankyo Propharma Co., Ltd. - April 22, 2016

Source: https://www.keypedia.com/records/fda_inspections/daiichi-sankyo-propharma-co-ltd/b66e57d2-e7ec-4f36-ba5a-30e3376b61e4
Source feed: FDA_Inspections

> FDA Inspection 971651 for Daiichi Sankyo Propharma Co., Ltd. on April 22, 2016. Classification: Voluntary Action Indicated (VAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 971651
- Company Name: Daiichi Sankyo Propharma Co., Ltd.
- Inspection Date: 2016-04-22
- Classification: Voluntary Action Indicated (VAI)
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research

## Related Documents

- [FDA Inspection 1105205 - 2019-08-29](https://www.keypedia.com/records/fda_inspections/daiichi-sankyo-propharma-co-ltd/5ecd1c44-2663-4872-8c14-fd069e1c1b1c)
- [FDA Inspection 1032011 - 2017-11-02](https://www.keypedia.com/records/fda_inspections/daiichi-sankyo-propharma-co-ltd/9070c8d4-53c7-4b95-bbd3-84d004ef030b)
- [FDA Inspection 888923 - 2014-06-13](https://www.keypedia.com/records/fda_inspections/daiichi-sankyo-propharma-co-ltd/988e56ba-7d00-49c6-978a-f57c0eec719e)

Company: https://www.keypedia.com/companies/daiichi-sankyo-propharma-co-ltd/d9bb5238-4acc-4fc5-8638-db754e816be8

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c